Clinical trials: First Pregnancy
Urinary Bladder, Overactive
FemPulse Therapy First-in-Human Experience
The purpose of this clinical trial is to investigate a new medical device treatment for Overactive Bladder (OAB) in women.
- Trial name
- NCT03874637
- Testing
- Treament
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- FemPulse Corporation
Kidney Failure, Chronic, Kidney Transplantation
Drone Transport of Deceased-Donor Kidney Grafts Between Two French Hospitals Before Transplantation: a Pilot Safety Study
Cold ischemia time, the period during which a donated kidney is kept cold outside the body between its removal from the donor and its transplantation into the recipient, is one of the main modifiable factors influencing how…
- Conditions
- Kidney Failure, Chronic, Kidney Transplantation, Delayed Graft Function, Cold Ischemia
- Trial name
- RAfALREIN (NCT07851571)
- Testing
- Kidney graft transport by autonomous unmanned aircraft (drone) between the procurement and transplantation centres
- Volunteers
- 5 people
- Sponsor
- Nantes University Hospital
Birth, First, Pregnancy Related
The Effect of the Continuous Midwifery Care Model on Birth Outcomes
It is the right of both the mother and her baby to receive the best care and give birth in the best way possible for every pregnant woman.
- Conditions
- Birth, First, Pregnancy Related, Newborn; Fit, Trauma, Psychological
- Trial name
- NCT06020339
- Testing
- The midwife-led continuous care model (MLCC)
- Where
- Turkey (Türkiye)
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Tarsus University
End Stage Renal Disease
Peridialysis Project: The Influence of Predialysis Factors on the Initial Course of Dialysis
The present study plans to delineate the clinical, biochemical, sociological and psychological factors. involved in dialysis preparation, and their impact on dialysis initiation (DI), modality choice and prognosis.
- Trial name
- Peridialysis (NCT02488200)
- Testing
- No intervention
- Where
- Denmark
- Volunteers
- 1,400 people
- Sponsor
- Herlev Hospital
Ovarian Cancer, Cervical Cancer
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors
- Conditions
- Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Non Small Cell Lung Cancer (NSCLC)
- Trial name
- NCT02988817
- Testing
- Enapotamab vedotin (HuMax-AXL-ADC)
- Where
- 41 sites in United States, Belgium and 4 more
- Volunteers
- 306 people
- Sponsor
- Genmab
Neurogenic Bladder
Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder
The purpose of this study is to investigate the use of Botulinum Toxin A as primary therapy for children with neurogenic bladder due to spina bifida and compare results with standard oral oxybutynin therapy.
- Trial name
- NCT01716624
- Testing
- Oxybutynin, Botulinum Toxin A injection
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Kidney Calculi
Initial Clinical Experience With the MONARCH Platform, Urology for the Treatment of Kidney Stones
The purpose of this study is to collect descriptive performance data using the MONARCH Platform, Urology (a novel robotic device) to perform mini-percutaneous nephrolithotomy (kidney stone removal) procedures.
- Trial name
- NCT05835323
- Testing
- Robotic-assisted mini-PCNL
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Auris Health, Inc.
Carcinoma, Renal Cell, Fumarate Hydratase Deficiency
Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma
This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of Sintilimab injection combined with Inlyta in fumarate hydratase-deficient renal cell carcinoma.
- Conditions
- Carcinoma, Renal Cell, Fumarate Hydratase Deficiency, Immunotherapy
- Trial name
- NCT04387500
- Testing
- Sintilimab injection plus Inlyta treatment
- Where
- China
- Volunteers
- 41 people
- Sponsor
- West China Hospital
Diabetes, Gestational
A Behavioral Intervention to Prevent Gestational Diabetes Mellitus
Gestational diabetes mellitus (GDM) increases the risk of adverse pregnancy outcome and developing type 2 diabetes after delivery.
- Trial name
- DIGITAL-G (NCT03987412)
- Testing
- Lifestyle intervention with APP
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Peking University Third Hospital
Ovarian Cancer, Fallopian Tube Cancer
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
Multicenter, randomized, open label study including patients with advanced HRDpositive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary with no residual tumor mass…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma
- Trial name
- N-Plus (NCT05460000)
- Testing
- 3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy
- Where
- 50 sites in Austria, Belgium and 4 more
- Volunteers
- 640 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Ovarian Cancer
Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.
The purpose of this study is to determine if either of two doses of EMD 273066 when given with a low dose of cyclophosphamide will result in a second time to progression that is as long or longer than the first time to progression
- Trial name
- NCT00408967
- Testing
- Tucotuzumab celmoleukin (EMD 273066)
- Sponsor
- EMD Serono
Ovarian Cancer, Fallopian Tube Cancer
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
- Trial name
- NCT03740165
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 227 sites in United States, Australia and 20 more
- Volunteers
- 1,367 people
- Sponsor
- Merck Sharp & Dohme LLC
Clear Cell Renal Cell Carcinoma
1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
The main purpose of this study is to find out how useful dovitinib is when given as the initial treatment to participants with advanced kidney cancer, that has spread to other parts of the body.
- Trial name
- DILIGENCE-1 (NCT01791387)
- Testing
- Dovitinib
- Where
- New Zealand
- Volunteers
- 30 people
- Sponsor
- Auckland District Health Board
Ovarian Neoplasms
Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study
In order to explore the real situation of niraparib in clinical application more comprehensively and deeply, we conducted the first multicenter, real-world study in China.
- Trial name
- NCT05734911
- Testing
- Niraparib
- Where
- China
- Volunteers
- 199 people
- Sponsor
- Zhongda Hospital
Ovary Cancer
Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK
This is a retrospective observational medical records review study of BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting in France, Italy and the UK.
- Trial name
- OVAL-1 (NCT04532645)
- Testing
- Olaparib
- Where
- 55 sites in France, Italy and 1 more
- Volunteers
- 342 people
- Sponsor
- AstraZeneca
Infertility, Female, First Trimester Spontaneous Abortion
Determination of Circulating Placental Biomarkers Levels to Predict the Pregnancy Outcome of First Trimester After IVF.
This study will assess the predictive potential of circulating placental biomarkers for spontaneous miscarriage within the following month in an IVF setting.
- Trial name
- NCT04387994
- Testing
- Blood samples collection
- Where
- Portugal
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Instituto Valenciano de Infertilidade de Lisboa
Breast Cancer, Solid Tumors, Adult
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid…
- Trial name
- PIKALO-1 (NCT05768139)
- Testing
- STX-478, Fulvestrant, Ribociclib
- Where
- 65 sites in United States, Belgium and 7 more
- Volunteers
- 880 people
- Sponsor
- Eli Lilly and Company
Endometrial Cancer
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
This is a German multi-center, prospective, non-interventional study (NIS) to collect real-world clinical data in patients with primary advanced (FIGO stage III or IV) or recurrent endometrial cancer (EC) receiving first-line…
- Trial name
- DUOLife (NCT06890273)
- Where
- 49 sites in Germany
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
End Stage Renal Disease
Initial Safety Study of the TRUE AVC in Hemodialysis Access (TRUE AVC I Study)
Prospective, nonrandomized, single-arm, single-center, open-label, initial safety study in subjects requiring hemodialysis. Subjects will be followed with physical evaluation and ultrasound vessel imaging at days 15, 29, 57 and…
- Trial name
- NCT05567757
- Testing
- Arteriovenous conduit implant
- Where
- Panama
- Volunteers
- 11 people
- Sponsor
- Vascudyne, Inc.
Early Pregnancy Loss, Delayed Pregnancy Loss
CCT-102 or Expectant Management in Delayed Pregnancy Loss
A Phase 3, multi-center clinical trial of a CCT-102 regimen or expectant management to promote uterine evacuation in first trimester non-progressing Delayed Pregnancy Loss (DPL).
- Trial name
- MERMAID (NCT06121063)
- Testing
- CCT-102 A and CCT-102 B
- Where
- 15 sites in United States
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Conceptra Biosciences, LLC